Research programme: monoclonal antibodies - NovelMed Therapeutics

Drug Profile

Research programme: monoclonal antibodies - NovelMed Therapeutics

Alternative Names: Anti-properdin antibody - NovelMed Therapeutics; BikazuMab; Neutralising monoclonal antibodies - NovelMedTherapeutics; NM 001; NM 3014

Latest Information Update: 19 May 2014

Price : $50

At a glance

  • Originator NovelMed Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C3-C5 convertases inhibitors; Cytokine inhibitors; Inflammation mediator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Age-related macular degeneration; Inflammation; Osteoarthritis; Paroxysmal nocturnal haemoglobinuria; Reperfusion injury; Rheumatic disorders
  • Research Renal failure

Most Recent Events

  • 15 May 2014 Pharmacodynamics data from a preclinical trial in Osteoarthritis released by NovelMed Therapeutics
  • 25 Sep 2013 Pharmacodynamics data from preclinical studies in Wet age-related macular degeneration released by NovelMed Therapeutics
  • 11 Sep 2013 Research programme: monoclonal antibodies - NovelMed Therapeutics is available for licensing as of 11 Sep 2013. http://www.novelmed.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top